The impact of basal cell carcinoma on the quality-of-life in older patients.
BaSQoL questionnaire
Basal cell carcinoma
HrQoL
Older adults
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
18 Sep 2024
18 Sep 2024
Historique:
received:
26
02
2024
accepted:
15
07
2024
medline:
18
9
2024
pubmed:
18
9
2024
entrez:
17
9
2024
Statut:
epublish
Résumé
Basal cell carcinoma (BCC) is the most frequent malignant tumour worldwide and incidences are rising rapidly. BCC grow locally, but can invade surrounding tissues. Little is known concerning their impact on the health-related quality of life (HrQoL), and limited available data reports contradicting results. Measuring HrQoL in BCC patients should be done using disease-specific questionnaires such as the Basal and Squamous cell carcinoma Quality of Life (BaSQoL) questionnaire. The aim of this study was to assess the BCC-related HrQoL by examining all relevant patient, tumour and treatment characteristics to identify the main factors for the BCC-related impact. Specific attention for older BCC patients wass brought forward because of the often complex decisions in this subgroup. Patients ≥ 18 years with a history of BCC were asked to fill in the BaSQoL questionnaire, consisting of 5 subdomains. Multivariable analyses were done using a generalized additive model (GAM) because of the need for incorporation of non-linear functions. The study obtained approval of the Ethics Committee of the Ghent University Hospital (EC/2019/1352). Informed consent was obtained from all subjects. All experiments were performed in accordance with relevant guidelines and regulations. Four hundred patients with a median age of 66 were enrolled. Mean BaSQoL subscores were 0.78 (SD 0.63) for 'behaviour', 1.01 (SD 0.73) for 'diagnosis&treatment', 0.90 (SD 0.73) for 'worries', 0.40 (SD 0.63) for 'appearance' and 1.20 (SD 0.75) for 'other people', illustrating the low to moderate impact of BCC on the HrQoL. A GAM with subsequent ANOVA testing was done for all relevant variables. In 4 out of 5 BaSQoL subdomains 'age' showed a significant correlation ('behaviour' p = 0.007; 'diagnosis&treatment' p = 0.026; 'worries' p = 0.003; 'appearance' p = 0.008). Lower BaSQoL scores were seen in older patients, meaning less BCC-impact on their HrQoL. There was a clear non-linear correlation between BaSQoL scores and age, illustrating that the impact of BCC on the HrQoL shows a rapid decrease starting around the age of 70. This study is the first to illustrate the relation between the BCC-related HrQoL and the age of patients with the use of a disease-specific HrQoL instrument. We found a lower BaSQoL score in older adults, with a specific age group of interest starting around the age of 70-75. This is an argument for a potential wait-and-see strategy for BCC in these patients.
Identifiants
pubmed: 39289416
doi: 10.1038/s41598-024-67740-0
pii: 10.1038/s41598-024-67740-0
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
21739Subventions
Organisme : Fonds Wetenschappelijk Onderzoek
ID : 1S69921N
Organisme : Fonds Wetenschappelijk Onderzoek
ID : 12Y2420N
Informations de copyright
© 2024. The Author(s).
Références
Flohil, S. C., de Vries, E., Neumann, H. A. M., Coebergh, J. W. W. & Nijsten, T. Incidence, prevalence and future trends of primary basal cell carcinoma in the Netherlands. Acta. Derm. Venereol. 91(1), 24–30 (2011).
doi: 10.2340/00015555-1009
pubmed: 21264452
van Walle L. Huidige situatie, trends & toekomst.
Van Coile, L. et al. The therapeutic dilemma of basal cell carcinoma in older adults: A review of the current literature. J. Geriatr. Oncol. 14(3), 101475 (2023).
doi: 10.1016/j.jgo.2023.101475
pubmed: 36990928
Hoorens, I. et al. Health state utility instruments in patients with keratinocyte cancer and actinic keratosis: A cross-sectional study. J. Eur. Acad. Dermatol. Venereol. 36(11), e906–e907 (2022).
doi: 10.1111/jdv.18349
pubmed: 35734826
Peris, K. et al. European consensus-based interdisciplinary guideline for diagnosis and treatment of basal cell carcinoma-update 2023. Eur J Cancer. 192, 113254 (2023).
doi: 10.1016/j.ejca.2023.113254
pubmed: 37604067
Siegel, J. A., Chren, M. M. & Weinstock, M. A. Department of veterans affairs keratinocyte carcinoma chemoprevention trial group. correlates of skin-related quality of life (QoL) in those with multiple keratinocyte carcinomas (KCs): A cross-sectional study. J. Am. Acad. Dermatol. 75(3), 639–642 (2016).
doi: 10.1016/j.jaad.2016.05.008
pubmed: 27543222
Rhee, J. S. et al. The skin cancer index: clinical responsiveness and predictors of quality of life. Laryngoscope. 117(3), 399–405 (2007).
doi: 10.1097/MLG.0b013e31802e2d88
pubmed: 17334300
pmcid: 1847346
Chen, T., Bertenthal, D., Sahay, A., Sen, S. & Chren, M. M. Predictors of skin-related quality of life after treatment of cutaneous basal cell carcinoma and squamous cell carcinoma. Arch. Dermatol. 143(11), 1386–1392 (2007).
doi: 10.1001/archderm.143.11.1386
pubmed: 18025362
Sanz Aranda, E., Bernal Martínez, Á. J., Reola Ramírez, E., Perales Enguita, A. & Martí Ayats, J. M. Quality of life in patients of advanced age with basal cell carcinoma: Analysis and implications for approach to treatment. Actas Dermosifiliogr. 113(5), 536–539 (2022).
doi: 10.1016/j.ad.2021.02.022
pubmed: 35697417
Waalboer-Spuij, R., Hollestein, L. M. & Nijsten, T. E. C. Group LV. satisfaction with information provision and health-related quality of life in basal and squamous cell carcinoma patients: A cross-sectional population-based study. Acta Derm. Venereol. 99(10), 933–934 (2019).
doi: 10.2340/00015555-3226
pubmed: 31120545
Gordon, L. G., Lindsay, D., Olsen, C. M. & Whiteman, D. C. Health utilities and health-related quality of life of patients with keratinocyte skin cancers. JEADV Clin. Pract. https://doi.org/10.1002/jvc2.227 (2023).
doi: 10.1002/jvc2.227
Charlson, M., Szatrowski, T. P., Peterson, J. & Gold, J. Validation of a combined comorbidity index. J. Clin. Epidemiol. 47(11), 1245–1251 (1994).
doi: 10.1016/0895-4356(94)90129-5
pubmed: 7722560
Linos, E. et al. Treatment of nonfatal conditions at the end of life: Nonmelanoma skin cancer. JAMA Int. Med. 173(11), 1006 (2013).
doi: 10.1001/jamainternmed.2013.639
Waalboer-Spuij, R., Hollestein, L. M., Timman, R., van de Poll-Franse, L. V. & Nijsten, T. E. Development and validation of the basal and squamous cell carcinoma quality of life (BaSQoL) questionnaire. Acta Derm. Venereol. 98(2), 234–239 (2018).
doi: 10.2340/00015555-2806
pubmed: 28952653